Switch theme
Sign up to access all valuation multiples
Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.
1933
1.2K+
LTM Revenue $623M
LTM EBITDA $148M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Faes Farma has a last 12-month revenue (LTM) of $623M and a last 12-month EBITDA of $148M.
In the most recent fiscal year, Faes Farma achieved revenue of $582M and an EBITDA of $151M.
Faes Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Faes Farma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $623M | XXX | $582M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $385M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $148M | XXX | $151M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $122M | XXX | $130M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $111M | XXX | $131M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Faes Farma's stock price is EUR 5 (or $5).
Faes Farma has current market cap of EUR 1.4B (or $1.7B), and EV of EUR 1.4B (or $1.6B).
See Faes Farma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.7B | XXX | XXX | XXX | XXX | $0.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Faes Farma has market cap of $1.7B and EV of $1.6B.
Faes Farma's trades at 2.8x EV/Revenue multiple, and 10.7x EV/EBITDA.
Equity research analysts estimate Faes Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Faes Farma has a P/E ratio of 15.1x.
See valuation multiples for Faes Farma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 13.4x | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.1x | XXX | 12.8x | XXX | XXX | XXX |
| EV/FCF | 26.3x | XXX | 18.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFaes Farma's last 12 month revenue growth is 13%
Faes Farma's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Faes Farma's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Faes Farma's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Faes Farma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Faes Farma acquired XXX companies to date.
Last acquisition by Faes Farma was XXXXXXXX, XXXXX XXXXX XXXXXX . Faes Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Faes Farma founded? | Faes Farma was founded in 1933. |
| Where is Faes Farma headquartered? | Faes Farma is headquartered in Spain. |
| How many employees does Faes Farma have? | As of today, Faes Farma has 1.2K+ employees. |
| Is Faes Farma publicy listed? | Yes, Faes Farma is a public company listed on MAD. |
| What is the stock symbol of Faes Farma? | Faes Farma trades under FAE ticker. |
| When did Faes Farma go public? | Faes Farma went public in 2015. |
| Who are competitors of Faes Farma? | Similar companies to Faes Farma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Faes Farma? | Faes Farma's current market cap is $1.7B |
| What is the current revenue of Faes Farma? | Faes Farma's last 12 months revenue is $623M. |
| What is the current revenue growth of Faes Farma? | Faes Farma revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Faes Farma? | Current revenue multiple of Faes Farma is 2.6x. |
| Is Faes Farma profitable? | Yes, Faes Farma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Faes Farma? | Faes Farma's last 12 months EBITDA is $148M. |
| What is Faes Farma's EBITDA margin? | Faes Farma's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Faes Farma? | Current EBITDA multiple of Faes Farma is 11.0x. |
| What is the current FCF of Faes Farma? | Faes Farma's last 12 months FCF is $61.7M. |
| What is Faes Farma's FCF margin? | Faes Farma's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Faes Farma? | Current FCF multiple of Faes Farma is 26.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
